{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:02:37Z","timestamp":1777982557343,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"FY2025 Kyoto University Hospital Research Fund for Young Scientists"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06902-8","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T07:10:16Z","timestamp":1772089816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hemostatic rescue with rFVIIa in Bernard\u2013Soulier syndrome refractory to HLA-matched platelet transfusion"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-8139","authenticated-orcid":false,"given":"Yusuke","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisaki","family":"Mizumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouhei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seita","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"3","key":"6902_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3324\/haematol.2010.039883","volume":"96","author":"MC Berndt","year":"2011","unstructured":"Berndt MC, Andrews RK (2011) Bernard-Soulier syndrome. Haematologica 96(3):355\u2013359. https:\/\/doi.org\/10.3324\/haematol.2010.039883","journal-title":"Haematologica"},{"issue":"4","key":"6902_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1055\/s-2000-8455","volume":"26","author":"DM Monroe","year":"2000","unstructured":"Monroe DM, Hoffman M, Allen GA, Roberts HR (2000) The factor VII\u2013platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost 26(4):373\u2013377. https:\/\/doi.org\/10.1055\/s-2000-8455","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"6902_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1046\/j.1365-2141.2003.04286.x","volume":"121","author":"AM Almeida","year":"2003","unstructured":"Almeida AM, Khair K, Hann I, Liesner R (2003) The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 121(3):477\u2013481. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04286.x","journal-title":"Br J Haematol"},{"issue":"Suppl 4","key":"6902_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1365-2516.2012.02842.x","volume":"18","author":"U Seligsohn","year":"2012","unstructured":"Seligsohn U (2012) Treatment of inherited platelet disorders. Haemophilia 18(Suppl 4):161\u2013165. https:\/\/doi.org\/10.1111\/j.1365-2516.2012.02842.x","journal-title":"Haemophilia"},{"issue":"5","key":"6902_CR5","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/trf.17824","volume":"64","author":"EJ Huisman","year":"2024","unstructured":"Huisman EJ, Holle N, Schipperus M, Cnossen MH, de Haas M, Porcelijn L, Zwaginga JJ (2024) Should HLA and HPA-matched platelet transfusions for patients with Glanzmann Thrombasthenia or Bernard-Soulier syndrome be standardized care? A Dutch survey and recommendations. Transfusion 64(5):824\u2013838. https:\/\/doi.org\/10.1111\/trf.17824","journal-title":"Transfusion"},{"issue":"3","key":"6902_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.tmrv.2007.03.003","volume":"21","author":"MC Poon","year":"2007","unstructured":"Poon MC (2007) The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transfus Med Rev 21(3):223\u2013236. https:\/\/doi.org\/10.1016\/j.tmrv.2007.03.003","journal-title":"Transfus Med Rev"},{"issue":"4","key":"6902_CR7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1538-7836.2005.01227.x","volume":"3","author":"T Lisman","year":"2005","unstructured":"Lisman T, Adelmeijer J, Cauwenberghs S, Van Pampus EC, Heemskerk JW, De Groot PG (2005) Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 3(4):742\u2013751. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01227.x","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"6902_CR8","first-page":"S61","volume":"9","author":"M Hoffman","year":"1998","unstructured":"Hoffman M, Monroe DM 3rd, Roberts HR (1998) Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 9(Suppl 1):S61-5","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"6902_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2450\/2008.0015-08","volume":"7","author":"M Franchini","year":"2009","unstructured":"Franchini M (2009) The use of recombinant activated factor VII in platelet disorders: a critical review of the literature. Blood Transfus 7(1):24\u201328. https:\/\/doi.org\/10.2450\/2008.0015-08","journal-title":"Blood Transfus"},{"issue":"6","key":"6902_CR10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1046\/j.1365-2516.1998.00209.x","volume":"4","author":"JM Lusher","year":"1998","unstructured":"Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A et al (1998) A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa study group. Haemophilia 4(6):790\u20138. https:\/\/doi.org\/10.1046\/j.1365-2516.1998.00209.x","journal-title":"Haemophilia"},{"issue":"5","key":"6902_CR11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1023\/b:ddas.0000030105.72874.ff","volume":"49","author":"O Y\u00fcksel","year":"2004","unstructured":"Y\u00fcksel O, K\u00f6kl\u00fc S, U\u00e7ar E, Sa\u015fmaz N, Sahin B (2004) Severe recurrent gastrointestinal bleeding due to angiodysplasia in a Bernard-Soulier patient: an onerous medical concomitance. Dig Dis Sci 49(5):885\u2013887. https:\/\/doi.org\/10.1023\/b:ddas.0000030105.72874.ff","journal-title":"Dig Dis Sci"},{"issue":"12","key":"6902_CR12","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00277-005-1080-y","volume":"84","author":"MC Ozelo","year":"2005","unstructured":"Ozelo MC, Svirin P, Larina L (2005) Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. Ann Hematol 84(12):816\u2013822. https:\/\/doi.org\/10.1007\/s00277-005-1080-y","journal-title":"Ann Hematol"},{"issue":"3","key":"6902_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.thromres.2006.10.018","volume":"120","author":"A Hacihanefioglu","year":"2007","unstructured":"Hacihanefioglu A, Tarkun P, Gonullu E (2007) Use of recombinant factor VIIa in the management and prophylaxis of bleeding episodes in two patients with Bernard-Soulier syndrome. Thromb Res 120(3):455\u2013457. https:\/\/doi.org\/10.1016\/j.thromres.2006.10.018","journal-title":"Thromb Res"},{"issue":"1","key":"6902_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2516.2008.01902.x","volume":"15","author":"KL Tefre","year":"2009","unstructured":"Tefre KL, Ingerslev J, S\u00f8rensen B (2009) Clinical benefit of recombinant factor VIIa in management of bleeds and surgery in two brothers suffering from the Bernard-Soulier syndrome. Haemophilia 15(1):281\u2013284. https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01902.x","journal-title":"Haemophilia"},{"issue":"2","key":"6902_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.14740\/jmc3142w","volume":"9","author":"S Boppana","year":"2018","unstructured":"Boppana S, Ismail F, Singh G, Sonkodi S, Brown S (2018) Perioperative use of recombinant activated factor VII in a patient with Bernard\u2013Soulier syndrome. J Med Cases 9(2):44\u201346. https:\/\/doi.org\/10.14740\/jmc3142w","journal-title":"J Med Cases"},{"issue":"8","key":"6902_CR16","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1007\/s00277-023-05287-2","volume":"103","author":"M Shima","year":"2024","unstructured":"Shima M (2024) Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven\u00ae, in the treatment of haemophilia and rare bleeding disorders. Ann Hematol 103(8):2647\u20132658. https:\/\/doi.org\/10.1007\/s00277-023-05287-2","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06902-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06902-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06902-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:44Z","timestamp":1776405584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06902-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6902"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06902-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8072327\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The administration of recombinant activated factor VII (rFVIIa) in this patient with Bernard\u2013Soulier syndrome was an off-label intervention performed under emergency circumstances, as conventional hemostatic therapies had failed to achieve bleeding control. Due to the urgent nature of the situation, formal approval from the institutional review board (IRB) was not obtained prior to treatment. However, the patient was fully informed of the off-label use, potential risks, and anticipated benefits, and provided written informed consent for the treatment. The management was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}